Mayinglong Pharmaceutical Group Co., Ltd. (SHA:600993)

SHA:600993 Balance Sheet

Financials in millions CNY. Fiscal year is January - December.

Fiscal Year	TTM	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020
Period Ending	Mar 31, 2025	Dec 31, 2024	Dec 31, 2023	Dec 31, 2022	Dec 31, 2021	Dec 31, 2020
Cash & Equivalents	1,749	3,015	2,988	2,494	2,431	2,073
Short-Term Investments	-	-	-	138.81	142.01	215.37
Trading Asset Securities	1,166	142.14	63.29	674.35	106.02	36.32
Cash & Short-Term Investments	2,916	3,157	3,051	3,307	2,679	2,325
Cash Growth	-3.77%	3.48%	-7.72%	23.45%	15.22%	42.20%
Accounts Receivable	650.68	457.05	334.67	409.64	242.87	380.41
Other Receivables	65.06	10.44	42.57	44.98	24.94	21
Receivables	715.74	467.49	377.24	454.62	267.81	401.41
Inventory	270.73	277.63	273.48	336.2	313.92	268.16
Other Current Assets	68.94	72.6	69.48	128.18	100.85	117.05
Total Current Assets	3,971	3,975	3,772	4,226	3,361	3,111
Property, Plant & Equipment	772.75	770.89	635.53	515.34	440.44	344.06
Long-Term Investments	153.88	148.95	152.83	151.47	176.79	226.08
Goodwill	25.26	25.26	25.26	25.26	25.26	25.26
Other Intangible Assets	91.55	93.09	90.11	37.28	36.9	34.11
Long-Term Deferred Tax Assets	55.14	50.59	49.46	58.36	21.63	21.03
Long-Term Deferred Charges	120.44	113.4	82.3	66.52	58.44	61.38
Other Long-Term Assets	257.38	4.6	22.46	8.14	6.27	43.24
Total Assets	5,448	5,182	4,830	5,088	4,127	3,866
Accounts Payable	350.15	337.66	289.69	284.74	156.82	152.31
Accrued Expenses	25.18	35.22	82.51	118.5	141.79	190.95
Short-Term Debt	12	31.8	45.8	88.1	88	133
Current Portion of Long-Term Debt	122.35	126.22	9.79	-	-	-
Current Portion of Leases	-	-	23.12	28.13	21.14	-
Current Income Taxes Payable	124.01	85.65	36.24	70.98	60.42	57.98
Current Unearned Revenue	108.98	86.84	91.86	102.75	88.18	183.41
Other Current Liabilities	120.46	100.96	102.07	164.94	109.08	83.77
Total Current Liabilities	863.13	804.36	681.07	858.14	665.44	801.43
Long-Term Debt	-	-	100	400	-	-
Long-Term Leases	77.07	76.2	93.59	122	73.21	-
Long-Term Unearned Revenue	50.85	54.56	27.89	26.95	29.03	17.03
Long-Term Deferred Tax Liabilities	22.43	23.5	28.61	35.37	2.51	2.93
Other Long-Term Liabilities	23.36	22.04	28.46	29.54	42.53	98.5
Total Liabilities	1,037	980.66	959.62	1,472	812.72	919.89
Common Stock	431.05	431.05	431.05	431.05	431.05	431.05
Additional Paid-In Capital	23.53	23.53	51.51	100.74	105.2	118.11
Retained Earnings	3,812	3,608	3,253	2,960	2,634	2,299
Comprehensive Income & Other	2.91	2.96	2.66	2.46	1.28	1.66
Total Common Equity	4,269	4,066	3,738	3,495	3,171	2,849
Minority Interest	141.3	135.32	131.94	121.5	142.82	97.16
Shareholders' Equity	4,411	4,201	3,870	3,616	3,314	2,947
Total Liabilities & Equity	5,448	5,182	4,830	5,088	4,127	3,866
Total Debt	211.42	234.22	272.29	638.23	182.35	133
Net Cash (Debt)	2,704	2,923	2,779	2,669	2,496	2,192
Net Cash Growth	-2.05%	5.19%	4.14%	6.90%	13.90%	37.37%
Net Cash Per Share	6.29	6.81	6.46	6.19	5.80	5.07
Filing Date Shares Outstanding	433.13	422.56	431.05	431.05	431.05	431.05
Total Common Shares Outstanding	433.13	422.56	431.05	431.05	431.05	431.05
Working Capital	3,108	3,171	3,091	3,368	2,696	2,310
Book Value Per Share	9.86	9.62	8.67	8.11	7.36	6.61
Tangible Book Value	4,153	3,948	3,623	3,432	3,109	2,790
Tangible Book Value Per Share	9.59	9.34	8.40	7.96	7.21	6.47
Buildings	-	-	290.61	293.35	290.37	277.13
Machinery	-	-	401.77	402.1	292.67	277.89
Construction In Progress	-	-	205.74	25.71	8.75	34.76

Source: S&P Global Market Intelligence. Standard template. Financial Sources.